碘甲基膦酸二乙酯 | 10419-77-9

• 物质功能分类: 化学试剂 - 有机试剂 - 膦酸酯/膦酸盐
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 中文名称: 碘甲基膦酸二乙酯
• 中文别名: 碘甲基磷酸二乙酯
• 英文名称: diethyl iodomethanephosphonate
• 英文别名: diethyl iodomethylphosphonate；diethyl α-iodomethylphosphonate；iodomethyl (diethyl)phosphonate；iodomethylphosphonic acid diethyl ester；Diethyl (iodomethyl)phosphonate；1-[ethoxy(iodomethyl)phosphoryl]oxyethane
• CAS: 10419-77-9
• 化学式: C₅H₁₂IO₃P
• mdl: MFCD00041386
• 分子量: 278.027
• InChiKey: PNFHTBDRPOJJTQ-UHFFFAOYSA-N

物化性质

• 沸点：
  112-114 °C (1 mmHg)
• 密度：
  1.6606 g/cm3(Temp: 19 °C)
• 闪点：
  112-114°C/1mm
• 稳定性/保质期：

  遵照规格使用和储存则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  密封于阴凉干燥处。

SDS

Name:	Diethyl Iodomethylphosphonate Material Safety Data Sheet
Synonym:	None Known
CAS:	10419-77-9

Section 1 - Chemical Product MSDS Name:Diethyl Iodomethylphosphonate Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
10419-77-9	Diethyl Iodomethylphosphonate	ca. 100	233-895-3

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use only in a chemical fume hood. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 10419-77-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: clear colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 112 - 114 deg C @ 1 mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H12IO3P
Molecular Weight: 277.96

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of phosphorus, carbon dioxide, hydrogen iodide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 10419-77-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Diethyl Iodomethylphosphonate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 10419-77-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 10419-77-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 10419-77-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  碘甲基膦酸二乙酯 生成 diethyl 1-phenylselenylpentylphosphonate
  参考文献：
  名称：

  The reaction of selenophosphonates with carbonyl compounds. Vinylic selenides

  摘要：

  DOI：

  10.1016/s0022-328x(00)90648-x
• 作为产物：
  描述：

  对甲苯磺酰氧甲基膦酸二乙酯 在 sodium iodide 作用下， 以 丙酮 为溶剂， 反应 24.0h， 生成 碘甲基膦酸二乙酯
  参考文献：
  名称：

  通过铜(I)-催化的α,β-不饱和砜的1,4-共轭甲硅烷基化和随后的Julia-Kocienski 烯烃不对称合成手性1,3-二取代烯丙基硅烷

  摘要：

  手性 1,3-二取代烯丙基硅烷的一般合成是通过铜 (I) 催化的 α,β-不饱和砜的不对称 1,4-共轭硅烷化和随后的 Julia-Kocienski 烯化建立的。通过修饰 McQuade 的 NHC 配体，以高对映选择性实现了具有广泛底物范围的催化不对称共轭硅烷化。以下Julia-Kocienski 烯化在室温下顺利进行，以中等产率提供一系列手性烯丙基硅烷。更有趣的是，成功实现了具有高合成效率的一锅不对称合成。在醛和醛亚胺的不对称烯丙基化中证明了制备的手性 1,3-二取代烯丙基硅烷的效用。最后，在手性醛的不对称烯丙基化中观察到了一个有趣的“匹配和错配”现象。

  DOI：

  10.1002/cjoc.202100101
• 作为试剂：
  描述：

  1-庚烯 、 偶氮二异丁腈 在 碘甲基膦酸二乙酯 作用下， 以 苯 为溶剂， 生成 4-iodo-2,2-dimethylnonanenitrile
  参考文献：
  名称：

  AIBN引发的分子间碘原子转移加成反应（I-ATRA）中的两种引发途径

  摘要：

  4-碘-2,2-二甲基辛腈和2-碘-2-甲基丙腈的检测证明了I-ATRA反应中两种类型（I和II）引发的操作。EWG-CH(R)-I [R = H, Me ; EWG = (EtO)2P(O), (-)-(MenthylO)2 P(O), CN, Br-C6H4C(O), MeO(O)C, 烯丙基] 与 1-己烯。在 (EtO)2P(O)CH(R)-I 与 1-庚烯、1-庚炔、环戊烯、环己烯和炔丙醇的反应中也检测到类似结构的腈。2-碘-2-甲基丙腈作为异丁腈攻击起始碘化物的碘原子的产物在烯丙基碘和1-己烯的反应中首次被检测到，并证明了协同引发途径的操作（I型）。直接在光谱仪腔中进行的 EPR 实验证实了极低浓度的反应自由基物质（对于样品中 c = 0.1 mol/dm3、<10-8 mol/dm3 或 <10-12 摩尔自旋的样品）在涉及低反应性 1-碘代烷基膦酸酯的 I-ATRA 反应中。©

  DOI：

  10.1002/hc.20116

文献信息

• NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME
  申请人：Ryono Denis E.

  公开号：US20080009465A1

  公开（公告）日：2008-01-10

  Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R 4 is —(CH 2 ) n -Z-(CH 2 ) m —PO(OR 7 )(OR 8 ), —(CH 2 ) n Z-(CH 2 ) m —PO(OR 7 )R g , —(CH 2 ) n -Z-(CH 2 ) m —OPO(OR 7 )R g , —(CH 2 ) n Z—(CH 2 ) m —OPO(R 9 )(R 10 ), or —(CH 2 ) n Z—(CH 2 ) m —PO(R 9 )(R 10 ); R 5 and R 6 are independently selected from H, alkyl and halogen; Y is R 7 (CH 2 ) s or is absent; and X, n, Z, m, R 4 , R 5 , R 6 , R 7 , and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.

  提供了磷酸酯和磷酸酯激活剂，因此在治疗糖尿病和相关疾病方面非常有用，并具有以下结构： 其中 是杂环芳基环； R 4 为—(CH 2 ) n -Z-(CH 2 ) m —PO(OR 7 )(OR 8 )、—(CH 2 ) n Z-(CH 2 ) m —PO(OR 7 )R g 、—(CH 2 ) n -Z-(CH 2 ) m —OPO(OR 7 )R g 、—(CH 2 ) n Z—(CH 2 ) m —OPO(R 9 )(R 10) 或—(CH 2 ) n Z—(CH 2 ) m —PO(R 9 )(R 10) ； R 5 和R 6 分别选择自H、烷基和卤素； Y为R 7 (CH 2 ) s 或不存在；以及 X、n、Z、m、R 4 、R 5 、R 6 、R 7 和s如本文所定义；或其药用盐。 还提供了一种利用上述化合物治疗糖尿病和相关疾病的方法。
• [EN] NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME<br/>[FR] NOUVEAUX ACTIVATEURS DE LA GLUCOKINASE ET MÉTHODES D'UTILISATION DESDITS ACTIVATEURS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011130459A1

  公开（公告）日：2011-10-20

  Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structure wherein R1, R2, R3, R4, R5, R6, Y and X are as defined herein or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related disease employing the above compounds is also provided.

  提供了一些化合物，这些化合物是葡萄糖激酶的激活剂，因此在治疗糖尿病和相关疾病方面很有用，这些化合物的结构式中，R1、R2、R3、R4、R5、R6、Y和X如本文所述，或其药用可接受盐。还提供了一种使用上述化合物治疗糖尿病和相关疾病的方法。
• Solid-Phase Synthesis of Peptide Vinyl Sulfones as Potential Inhibitors and Activity-Based Probes of Cysteine Proteases
  作者：Gang Wang、Uttamchandani Mahesh、Grace Y. J. Chen、Shao Q. Yao

  DOI：10.1021/ol0275567

  日期：2003.3.1

  Peptide vinyl sulfones were prepared from 2-chlorotrityl resin-bound phenolic amino vinyl sulfones in high yield and purity. This method enables the convenient synthesis of peptide vinyl sulfones having different amino acids at the P(1) position. It also allows efficient synthesis of vinyl sulfone-containing, activity-based probes of cysteine proteases used in a proteomic experiment.

  由2-氯三苯甲基树脂结合的酚氨基乙烯基乙烯基砜以高收率和纯度制备了肽乙烯基砜。该方法能够方便地合成在P（1）位置具有不同氨基酸的肽乙烯基砜。它还可以有效合成蛋白质组学实验中使用的含乙烯基砜，基于活性的半胱氨酸蛋白酶探针。
• Novel structural analogs of glyphosate based on azoles. 2*. N-Substituted imidazoles and pyrazoles obtained by alkylation of heterocycles containing carboxyl or phosphoryl groups in the ring
  作者：N. V. Pavlenko、T. I. Oos、N. V. Kirij、Yu. L. Yagupolskii、A. van Almsick、L. Willms

  DOI：10.1007/s10593-011-0777-1

  日期：2011.7

  Alkylation of 4(5)-substituted 1H-imidazoles using the corresponding reagents gave imidazole 1,4-isomers containing phosphoryl and carboxyl groups together in the ring and in the alkyl fragment. The alkylation of pyrazoles containing a carboxyl group at positions 3(5) and 4 of the ring using diethyl phosphonomethyltriflate has been studied.

  使用相应的试剂对4（5）-取代的1H-咪唑进行烷基化反应，得到在环和烷基片段中一起含有磷酰基和羧基的咪唑1,4-异构体。已经研究了使用二乙基膦酰基甲基三氟甲磺酸酯在环的3（5）和4位上含有羧基的吡唑的烷基化。
• [EN] PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS PYRIMIDINES EN TANT QU'INHIBITEURS DE KINASE
  申请人：ICAHN SCHOOL MED MOUNT SINAI

  公开号：WO2014151682A1

  公开（公告）日：2014-09-25

  This disclosure relates to compounds, methods for their preparation, pharmaceutical compositions including these compounds and methods for the treatment of cellular proliferative disorders, including, but not limited to, cancer.

  这份披露涉及化合物、它们的制备方法、包括这些化合物的药物组合物以及治疗细胞增殖障碍的方法，包括但不限于癌症。